Fairvalue-Calculator Fairvalue-Calculator

ChongQing Zhengchuan Pharmaceutical Packaging Co (603976) Fair Value & Analysis

Consumer Cyclical · CN · Market cap 4.1B CNY

Price¥28.12
Fair Value¥3.34
Upside-88.1%
Quality95/100
Evidence: High Range ¥2.10 – ¥4.58

Analysis

ChongQing Zhengchuan Pharmaceutical Packaging Co (603976) currently trades at ¥28.12, while our model-based Fair Value estimate is ¥3.34 — implying the stock looks roughly 88.1% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

ChongQing Zhengchuan Pharmaceutical Packaging Co.,Ltd engages in the research and development, manufacturing, and selling of pharmaceutical glass packaging materials in China and internationally. It offers neutral borosilicate glass ampoule and tube injection bottles, low borosilicate tubular vial and ampoule bottles, oral liquid vials, and screw neck vials. The company also provides aluminum caps, aluminum-plastic composite caps, and other medicinal caps. Its products are used in biological preparations, traditional Chinese medicine preparations, and chemical medicines. The company was founded in 1988 and is headquartered in Chongqing, China.

Open the full interactive analysis →

Similar stocks

Smurfit Kappa Group (SMFTF) -30% Smurfit Westrock Plc, (SW) -1% Packaging Corporation (PKG) -43% International Paper Company (IP) +130% Amcor plc (AMCR) -55% Ball Corporation (B1LL34) -87%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.